NUR 7600 Module 4 Lifespan and Controlled Substances Case: Methylphenidate for a 9-Year-Old Example

Schedule II at Age Nine: Extended-Release Methylphenidate, Parent Training and the Rules for Prescribing a Stimulant to a Third Grader

Student Name

M.S. in Nursing, Psychiatric Mental Health Nurse Practitioner, Thomas Edison State University

NUR-7600: Psychopharmacology and Neuroscience Foundations Across the Lifespan

Mentor Name

Month Day, Year

Schedule II at Age Nine: Extended-Release Methylphenidate, Parent Training and the Rules for Prescribing a Stimulant to a Third Grader

Introduction

Mateo is an invented patient, a 9-year-old third grader in Elizabeth who lives with his mother, a home health aide, and his grandmother. His teacher reports that he cannot stay seated, interrupts constantly, loses his work and has fallen a year behind in reading. At home he needs repeated reminders for every task, and homework takes hours. These problems have been present since kindergarten and occur in both settings. Parent and teacher Vanderbilt rating scales are positive for both inattentive and hyperactive-impulsive symptoms, with impairment in school and family life. His hearing, vision and sleep are normal, he has no history of cardiac symptoms or sudden death in the family, and screening for anxiety, depression and learning disability is negative, though a reading evaluation is pending. The diagnosis is ADHD of the combined type. His mother is open to medication but worried that it will change his personality and that it is "a drug like cocaine."

What the Guideline Recommends

For children aged six to eleven, the AAP's 2019 guidance (Wolraich et al., 2019) asks for an FDA-approved medicine paired with behavior training for parents and behavioral supports in the classroom, ideally all three. Stimulants are recommended as first-line medication because of the strength of the evidence. The guideline also calls for treating ADHD as a chronic condition, with regular follow-up and attention to coexisting conditions.

Evidence on Medication and Behavioral Treatment

In the MTA study, 579 children were assigned by chance to closely managed medicine, intensive behavior therapy, both, or whatever their community offered, and followed for 14 months (MTA Cooperative Group, 1999). Children whose medicine was managed closely, with or without behavior therapy, ended up with fewer core symptoms than those given behavior therapy alone or ordinary community care. The combined approach offered some additional benefits for outcomes such as oppositional behavior and parent-child relations, and allowed somewhat lower medication doses. For Mateo's family, this supports medication as the core of symptom treatment and parent training as a partner rather than an alternative.

Cortese et al. (2018) set 133 randomized trials against one another in a single network. In children and adolescents, all drugs were superior to placebo on clinician ratings, with amphetamines showing the largest effect, followed by methylphenidate. On teacher ratings, only methylphenidate and modafinil were clearly superior to placebo. Amphetamines were less well tolerated than placebo in children, while methylphenidate was not. Their bottom line put methylphenidate first for young people and amphetamines first for adults.

How Methylphenidate Works

Methylphenidate blocks the dopamine and norepinephrine transporters, increasing these transmitters in the synapse, particularly in the prefrontal cortex, where they support attention, working memory and inhibition of impulses. Its effect begins within an hour and lasts only as long as the drug is present, which is why extended-release forms are used to cover the school day. Unlike cocaine, which enters the brain rapidly when smoked or snorted and produces a sharp rise and fall in dopamine, oral methylphenidate taken as prescribed raises dopamine slowly and steadily, which is why it does not produce euphoria in most children. That difference addresses the mother's concern directly.

It also explains why the extended-release form matters beyond convenience. An osmotic tablet releases the drug gradually over the day, so blood levels rise and fall smoothly, which further limits any rewarding effect and makes the tablet harder to misuse, since crushing it destroys the release mechanism.

The Prescription

Extended-release methylphenidate in the osmotic-release form, 18 milligrams by mouth each morning with breakfast, swallowed whole. The dose will be increased by 18 milligrams weekly, based on parent and teacher ratings and side effects, to the lowest dose that controls symptoms, up to 54 milligrams for his age. Rating scales from his teacher and mother are collected at each step.

Methylphenidate is a Schedule II controlled substance under the federal Controlled Substances Act because of its potential for misuse. To write it, the nurse practitioner needs a federal DEA number covering Schedule II and New Jersey's own controlled substance registration. Schedule II prescriptions cannot be refilled; each fill requires a new prescription, though federal rules allow a prescriber to issue several prescriptions at one visit covering up to a 90-day supply, each marked with the earliest fill date. Electronic prescribing is the norm. Before prescribing, the nurse practitioner checks the New Jersey Prescription Monitoring Program, as state rules require, and documents the check.

Monitoring Across Development

Children are not small adults, and stimulants affect growth and cardiovascular measures. At each visit his height, weight, heart rate and blood pressure are recorded and plotted on growth charts. Lunch often goes uneaten on stimulants, so the dose rides with breakfast and supper is made the big meal. Sleep is monitored, since a late-day effect can delay sleep onset. Mood and tics are checked. He is seen monthly during titration and every three months once stable.

Diversion and Safety

Stimulants are among the most commonly misused prescription drugs among adolescents and young adults. Although Mateo is 9, the family is taught to store the medicine locked, count the tablets, never share them and report losses. The school receives a care plan, and if a school dose is ever needed, the school nurse holds it.

Parent Training and School Supports

His mother and grandmother are signed up for a behavior management course for parents, and a letter goes to his school asking it to assess him for a Section 504 plan or special education because of his reading lag. Behavioral classroom supports, such as a daily report card, are suggested.

Conclusion

For a 9-year-old with combined-presentation ADHD, the guideline, the MTA trial and comparative evidence support methylphenidate as first-line medication with parent training. As a Schedule II drug, it is prescribed with registrations, a monitoring program check and no refills, and growth, blood pressure and sleep are followed as he develops. His mother's fears are answered with the pharmacology that separates oral methylphenidate from drugs of abuse.

References

Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.-C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727-738. https://doi.org/10.1016/S2215-0366(18)30269-4

MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56(12), 1073-1086. https://doi.org/10.1001/archpsyc.56.12.1073

Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), Article e20192528. https://doi.org/10.1542/peds.2019-2528